Mandate

Vinge advises Jarðvarmi och Ancala Partners in connection with the acquisition of Magma Energy Sweden AB and HS Orka

June 13, 2019 M&A

Vinge has advised Jarðvarmi slhf., a consortium of 14 Icelandic pension funds, and Ancala Partners’ mid-market focused infrastructure fund Ancala Infrastructure Fund II in questions regarding Swedish law in connection with the acquisition of Magma Energy Sweden AB and its subsidiary HS Orka, Iceland’s largest private electricity generator.

In connection with the transaction, Jarðvarmi exercised its right of first refusal to acquire a 53.9% interest in HS Orka from Alterra Power Corp, a subsidiary of Innergex Renewable Energy Inc. Jarðvarmi has also agreed to acquire a 12.7% interest in HS Orka from Fagfjárfestasjóðurinn ORK. The remaining 33.4% in HS Orka was already owned by Jarðvarmi. Following the transactions Ancala Partners and Jarðvarmi will each own 50% of HS Orka.

The purchase price for the acquisition of Alterra’s 53.9% interest was USD 299.9 million. The purchase price for the acquisition of Fagfjárfestasjóðurinn ORK’s 12.7% interest was not disclosed. 

Ancala Partners and Jarðvarmi have further agreed to divest HS Orka’s 30% interest in the Blue Lagoon, Iceland’s leading tourist attraction, to Blávarmi. The sale transitions HS Orka into a pure play renewable energy platform. HS Orka has been producing renewable energy for 40 years and operates two geothermal powerplants, Svartsengi and Reykjanes, as well as a hydro powerplant at Bláskógabyggð.

The Vinge team consisted of partner Peter Sundgren and associate Christina Odengran. Counsel Maria Schultzberg advised in tax matters. 

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026